SCHEMBL19852262

SCHEMBL19852262

CCOC(=O)C1Cc2ccncc2C1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.63
ALDH1A1 P00352 5/20 0.63
KDM4E B2RXH2 4/20 0.63
KMT2A Q03164 3/20 0.63
MEN1 O00255 2/20 0.63
GAA P10253 2/20 0.63
HPGD P15428 1/20 0.63
HSD17B10 Q99714 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.44
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.39
NPEPPS P55786 1/20 0.38
MAPK1 P28482 1/20 0.37
ATM Q13315 1/20 0.37
ELANE P08246 1/20 0.36
KDM5A P29375 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
CYP11B1 P15538 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490810 0.80 MAPT (0.70) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL31460799 0.80 MAPT (0.70) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL2883707 0.79 MAPT (0.50) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL16153700 0.78 MAPT (0.76) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL15464941 0.75 KDM4E (0.67) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL6383092 0.75 ALDH1A1 (0.70) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL13156056 0.74 GAA (0.48) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL5782151 0.74 MAPT (0.47) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL17320354 0.74 KDM4E (0.85) MAPTALDH1A1KDM4EKMT2AMEN1
SCHEMBL19838889 0.74 CHRNB2 (0.43) MAPTALDH1A1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C MAPT 434/4885ALDH1A1 448/4885KDM4E 3373/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C MAPT 434/4885ALDH1A1 448/4885KDM4E 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.